Drug Makers Struggle to Replace Stimulants with Non-Addictive Alternatives hightimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hightimes.com Daily Mail and Mail on Sunday newspapers.
Feb 19, 2021 9:41am
The FDA hit India s Shilpa with an import alert on all but three of its drugs after the company failed to address problems cited in an October warning letter. (Pixabay/qimono)
Just a few months after India-based drugmaker Shilpa Medicare found itself in the FDA s crosshairs, the company now faces a ban on the vast majority of its products in the U.S.
The FDA slapped an import alert on Shilpa Medicare s formulation plant in Telangana, India, according to a notice posted Thursday. The product ban comes on the heels of an FDA warning letter that cited the Indian drugmaker for multiple manufacturing violations.